Cite
Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer.
MLA
Zhou, Tie, et al. “Preclinical Profile and Phase I Clinical Trial of a Novel Androgen Receptor Antagonist GT0918 in Castration-Resistant Prostate Cancer.” European Journal of Cancer, vol. 134, July 2020, pp. 29–40. EBSCOhost, https://doi.org/10.1016/j.ejca.2020.04.013.
APA
Zhou, T., Xu, W., Zhang, W., Sun, Y., Yan, H., Gao, X., Wang, F., Zhou, Q., Hou, J., Ren, S., Yang, Q., Yang, B., Xu, C., Zhou, Q., Wang, M., Chen, C., & Sun, Y. (2020). Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer. European Journal of Cancer, 134, 29–40. https://doi.org/10.1016/j.ejca.2020.04.013
Chicago
Zhou, Tie, Weidong Xu, Wei Zhang, Ye Sun, Honghua Yan, Xu Gao, Fubo Wang, et al. 2020. “Preclinical Profile and Phase I Clinical Trial of a Novel Androgen Receptor Antagonist GT0918 in Castration-Resistant Prostate Cancer.” European Journal of Cancer 134 (July): 29–40. doi:10.1016/j.ejca.2020.04.013.